Ethics approval and consent to participate

This retrospective study was approved by the Internal Review Board (IRB). The study was conducted according to the Declaration of Helsinki. The need for informed consent was waived as per IRB guidelines.

Consent for publication

Not applicable.

Competing interests

GG served as a scientific consultant for viTToria Biotherapeutics. MR holds patents related to CD19 CAR T cells, served as a consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Bayer, and AbClon, receives research funding from AbClon, NanoString, Oxford NanoImaging, viTToria biotherapeutics, CURIOX, and Beckman Coulter. MR is the scientific founder of viTToria Biotherapeutics. JS served as a consultant for Genmab, Adaptive, AstraZeneca, BMS, Imbrium, ADCT, Atara, Pharmacyclics, Seattle Genetics and received research funding from AstraZeneca, BMS, Incyte, Merck, Seattle Genetics, Pharmacyclics, and TG therapeutics. EAC served as a consultant for Novartis, Beigene, KITE, Tessa, and Juno/BMS. SKB served as a consultant to Acrotech, Kyowa Kirin, Daiichi Sankyo, and Seagen. SDN received research funding from Pharmacyclics, Roche, Rafael, FortySeven/Gilead. JDL received research funding from Curis, Takeda, and Triphase, and served on the Board of Directors or advisory committees or data and safety monitoring board for Incyte, ADCT, Karyopharm, and Morphosis. SJS served as a consultant to AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis, and Regeneron, received research funding from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics, and TG Therapeutics, received honoraria from Celgene and Novartis, and holds patents related to CD19 CAR T cells and autologous costimulated T cells. DLP: National Marrow Donor Program: Membership on an entity’s Board of Directors or advisory committees; Kite/Gilead: Membership on an entity’s Board of Directors or advisory committees; Janssen: Membership on an entity’s Board of Directors or advisory committees; Genentech: Current equity holder in publicly-traded company, ended employment in the past 24 months; American Society for Transplantation and Cellular Therapy: Honoraria; Incyte: Membership on an entity’s Board of Directors or advisory committees; DeCart: Membership on an entity’s Board of Directors or advisory committees; American Society of Hematology: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties, Research Funding; Tmunity: Patents & Royalties; Wiley and Sons Publishing: Honoraria. AG: Research support (via my institution) from Janssen, Novartis, Tmunity, and CRISPR therapeutics; Consultancies/honoraria from Janssen, Novartis, BMS, GSK, Legend Bio; DSMB membership for Janssen. All other authors declare no competing interests.